Aventis and Watson Reach Settlement on Litigation
Advertisement
Aventis Pharma AG, the pharmaceutical company of Aventis, announced today that it has settled litigation with Watson Pharmaceuticals Inc. related to the hypertension drug Dilacor® XR (dilatizem).
Terms of the settlement were not material to the financial position of Aventis, which previously had recorded reserves for potential liability in connection with the dispute.
The settlement relates to a lawsuit filed by Watson in a U.S. District Court in California in August 1999 against Rhone Poulenc Rorer Inc., a predecessor company of Aventis. The lawsuit alleged breach of a manufacturing and supply agreement and a non-compete clause contained in a 1997 license agreement granting certain rights to Dilacor XR® to Watson.